Mechanistic description
SARM1 is the executioner of axonal degeneration through its NMN hydrolase activity, and pharmacologic inhibition completely blocks Wallerian degeneration in acute injury models. Tool compounds (D-77, NVG-298) demonstrate in vivo efficacy in CIPN models, and Disarm Therapeutics has a Phase 1 program. The primary translational challenge is that ALS involves chronic multi-system failure rather than acute axotomy; SOD1 mouse models show only modest benefits from SARM1 deletion. Pursuing CIPN as an initial indication de-risks before ALS expansion.
Mechanism / pathway
- SARM1
- neurodegeneration
Evidence for (3)
SARM1 knockout completely blocks Wallerian degeneration
SARM1 inhibitors protect axons in CIPN models
SARM1 inhibitor in Phase 1 for peripheral neuropathy
Evidence against (2)
SARM1 KO x SOD1 mice show modest NMJ preservation but no survival benefit
SARM1 KO mice show impaired T-cell activation
Evidence matrix
Supporting
- SARM1 knockout completely blocks Wallerian degeneration PMID:20410109
- SARM1 inhibitors protect axons in CIPN models PMID:29361548
- SARM1 inhibitor in Phase 1 for peripheral neuropathy PMID:31535977
Contradicting
- SARM1 KO x SOD1 mice show modest NMJ preservation but no survival benefit PMID:31535977
- SARM1 KO mice show impaired T-cell activation PMID:29973723
Cite this hypothesis
Cite this hypothesis
envelope-repair (2026). Pharmacologic SARM1 blockade to prevent Wallerian degeneration after axotomy. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-0c78964fbd
@misc{scidex_hypothesis_h0c78964,
title = {Pharmacologic SARM1 blockade to prevent Wallerian degeneration after axotomy},
author = {envelope-repair},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-0c78964fbd},
note = {SciDEX artifact hypothesis:h-0c78964fbd}
}